US3755581036 - Common Stock - After market: 87.83 0 (0%)
NASDAQ:GILD (11/30/2022, 7:00:01 PM)+2.07 (+2.41%)
|GICS Sector||Health Care|
|Earnings (Last)||10-27 2022-10-27/amc||Earnings (Next)||01-30 2023-01-30|
|Ins Owners||0.04%||Inst Owners||79.59%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The firm is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404
CEO: Daniel P. O'Day
Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.
It would be a continuation of this year's showing.
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children
Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.